Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	181.32	238.16	84.31	72.85	19.42
Short-Term Investments	164.98	240.11	426.18	562.11	293.11
Cash & Cash Equivalents	346.3	478.28	510.49	634.96	312.53
Cash Growth	-27.59%	-6.31%	-19.60%	103.17%	-33.29%
Receivables	0.15	0	0	0	0
Inventory	10.37	0	0	0	0
Other Current Assets	-48.97	0.84	-2.54	1.14	3.96
Total Current Assets	307.85	479.12	507.96	636.1	316.49
Property, Plant & Equipment	176.55	178.25	169.92	113.92	19.23
Long-Term Investments	0	0	91.59	0	0
Goodwill and Intangibles	229.26	0	0	0	0
Other Long-Term Assets	66.7	6.62	7.87	18.44	8.93
Total Long-Term Assets	472.5	184.87	269.38	132.36	28.16
Total Assets	780.35	663.98	777.33	768.46	344.66
Accounts Payable	33.12	26.6	27.38	13.51	15.57
Current Debt	7.78	12.59	5.06	6.28	7.25
Other Current Liabilities	69.41	52.3	56.77	35.07	16.27
Total Current Liabilities	110.31	91.49	89.2	54.87	39.08
Long-Term Debt	68.09	72.86	66.47	45.38	4.25
Other Long-Term Liabilities	17.35	0	0	11.71	2.35
Total Long-Term Liabilities	85.43	72.86	66.47	57.09	6.6
Total Liabilities	195.74	164.34	155.67	111.96	45.68
Total Debt	75.86	85.45	71.53	51.66	11.5
Debt Growth	-11.22%	19.45%	38.47%	349.21%	-
Retained Earnings	-2,012.38	-1,568.34	-1,172.45	-830.19	-570.61
Comprehensive Income	2.53	-0.9	-0.6	0.02	0.22
Shareholders' Equity	584.61	499.64	621.66	656.5	298.97
Net Cash / Debt	270.44	392.83	438.96	583.3	301.03
Net Cash / Debt Growth	-31.16%	-10.51%	-24.75%	93.77%	-35.75%
Net Cash Per Share	1.15	2.47	2.86	4.22	2.42
Working Capital	197.54	387.63	418.76	581.23	277.41
Book Value Per Share	2.49	3.14	4.05	4.75	2.40

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).